# An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

> **NCT04971291** · PHASE2 · UNKNOWN · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 312 (estimated)

## Conditions studied

- Major Depressive Disorder
- Treatment Resistant Depression

## Interventions

- **DRUG:** AXS-05
- **DRUG:** Bupropion SR

## Key facts

- **NCT ID:** NCT04971291
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-14
- **Primary completion:** 2021-07
- **Final completion:** 2021-07
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971291, "An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04971291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*